Implicity received FDA clearance for its next-generation ILR ECG Analyzer, an AI-powered cloud software that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity for true cardiac events. The software works across devices from all major manufacturers, addressing the persistent issue of non-actionable alerts that burden clinicians. This innovation aims to improve workflow efficiency and patient care by ensuring only clinically relevant alerts reach healthcare providers. The product will be commercially available in the U.S. soon.
YieldMax ETFs announced weekly distributions for their Group 1 ETFs, with distribution rates ranging from 26.17% to 60.34% annualized. These ETFs cover sectors like semiconductors, AI & tech, crypto, metals, and covered call strategies. Distributions...
The global ultrasonic aspirator market, valued at $194 million in 2025, is projected to grow at a CAGR of 6.87% to reach $376 million by 2035. Growth is fueled by increased use in neurosurgery, orthopedic, and minimally invasive surgeries, driven by ...
MEXC's RealStocks platform, launched in June 2026, saw SpaceX (SPCX) capture nearly 30% of trading volume and user activity, marking it as the most popular stock among over 7,000 US stocks and ETFs available. AI-related stocks collectively accounted ...
The SCHD ETF currently offers a 3.3% yield and is on track to complete its 15th consecutive year of dividend increases in 2026. This consistent dividend growth highlights SCHD's appeal for income-focused investors seeking reliable payouts. Maintainin...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.26% ownership stake in Prologis Inc, totaling 11,789,090 shares as of July 27, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, indicating a significant investment po...
